Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595528 · ClinicalTrials.gov registry record · Phase 2
A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT02595528 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 163 participants.
The verdict
NCT02595528, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).
Interventions
- DRUG AGN-199201 ophthalmic solution
- DRUG AGN-190584 ophthalmic solution
- DRUG AGN-190584 vehicle
- DRUG AGN-199201 + AGN-190584 Combination
- DRUG AGN-199201 vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2016-04-29 |
| Est. Completion | 2017-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595528
The ClinicalTrials.gov registry entry for NCT02595528 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which AGN-199201 ophthalmic solution is the first listed.
NCT02595528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595528 about?
NCT02595528 is a clinical study titled "A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia". This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).
What is the current status of trial NCT02595528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2016-04-29. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT02595528?
The interventions under investigation include: AGN-199201 ophthalmic solution (DRUG), AGN-190584 ophthalmic solution (DRUG), AGN-190584 vehicle (DRUG), AGN-199201 + AGN-190584 Combination (DRUG), AGN-199201 vehicle (DRUG).
Who is sponsoring clinical trial NCT02595528?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.